iPS cell-derived platelet therapy (Astellas)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameiPS cell-derived platelet therapy (Astellas)
Drug Alias NameiPS cell-derived platelet therapy (Advanced Cell Technology)induced pluripotent stem cell-derived platelet therapy (Advanced Cell Technology)iPS cell-derived platelet therapy (Ocata)
ClassificationBiologics
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsWounds and InjuriesThrombocytopeniaCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsWounds and InjuriesThrombocytopeniaCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A